UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000054318
Receipt number R000061582
Scientific Title Verifying Characteristics and Outcomes in Heart Failure Patients Treated with Vericiguat: VERIFY-HF
Date of disclosure of the study information 2024/05/05
Last modified on 2024/05/05 23:50:52

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Verifying Characteristics and Outcomes in Heart Failure Patients Treated with Vericiguat: VERIFY-HF

Acronym

VERIFY-HF

Scientific Title

Verifying Characteristics and Outcomes in Heart Failure Patients Treated with Vericiguat: VERIFY-HF

Scientific Title:Acronym

VERIFY-HF

Region

Japan


Condition

Condition

Heart failure

Classification by specialty

Cardiology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate characteristics, adverse events, and outcomes in patients treated with vericiguat

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Adverse events related to vericiguat

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients with heart failure newly prescribed vericiguat from June 2021 to September 2023

Key exclusion criteria

Less than 20 years old

Target sample size

1000


Research contact person

Name of lead principal investigator

1st name Shingo
Middle name
Last name Matsumoto

Organization

Toho University Faculty of Medicine

Division name

Cardiology department

Zip code

143-8541

Address

6-11-1 Omorinishi, Otaku, Tokyo

TEL

0337624151

Email

shingomatsumoto0606@gmail.com


Public contact

Name of contact person

1st name Shingo
Middle name
Last name Matsumoto

Organization

Toho University Faculty of Medicine

Division name

Cardiology department

Zip code

143-8541

Address

6-11-1 Omorinishi, Otaku, Tokyo

TEL

0337624151

Homepage URL


Email

shingomatsumoto0606@gmail.com


Sponsor or person

Institute

Division of Cardiovascular Medicine, Department of Internal Medicine, Toho University Faculty of Medicine, Tokyo, Japan

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Toho University

Address

6-11-1 Omorinishi, Otaku, Tokyo

Tel

0337624151

Email

med.rinri@ext.toho-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

兵庫県立淡路医療センター、岩手医科大学附属病院、順天堂大学病院、慶応大学義塾大学病院、奈良県立医科大学、奈良県立医科大学、北里大学病院、国立循環器病研究センター、久留米大学病院、東海大学付属病院、大阪急性期・総合医療センター、日本医科大学、日本大学医学部附属板橋病院、近畿大学病院、聖マリアンナ医科大学、愛知医科大学、埼玉県立循環器呼吸器病センター、福岡赤十字病院、総合東京病院、小倉記念病院、大阪公立大学、千葉大学医学部附属病院、東邦大学医療センター大橋病院


Other administrative information

Date of disclosure of the study information

2024 Year 05 Month 05 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2024 Year 01 Month 11 Day

Date of IRB

2024 Year 01 Month 11 Day

Anticipated trial start date

2024 Year 05 Month 15 Day

Last follow-up date

2024 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Retrospective observational study enrolling patients with heart failure who were initiated vericiguat from 23th June 2021 to 31th September 2023.


Management information

Registered date

2024 Year 05 Month 05 Day

Last modified on

2024 Year 05 Month 05 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000061582